Co-Diagnostics, Inc. (CODX)

Co-Diagnostics, Inc.'s stock price has been impacted by several events, including a 1-for-30 reverse stock split to meet Nasdaq's minimum bid price requirement. Other notable events include the grant of an Australian patent covering Co-Dx PCR platform technologies and Co-Primers®, CoSara's participation in an advanced TB diagnostics course in Chennai, India, and Co-Diagnostics' analysis of Influenza Co-Primers® to confirm reactivity against the Flu A H3N2 mutation. The company presented on its Co-Dx™ PCR Platform and AI integration at Point-of-Care Testing 2025, announced the closing of a $3.8 million registered direct offering of common stock, and reported Q2 2025 results with a significant revenue decline. The company reported a net loss of $5.9 million on revenue of $0.1 million in Q3 2025, leading to a stock drop in after-hours trading. Overall, the stock has experienced high volatility, with its share price declining significantly over the past year.

There is evidence of demand seasonality for some of Co-Diagnostics, Inc.'s products, particularly its multiplex tests for respiratory illnesses such as Flu A, Flu B, COVID-19, and RSV. Co-Diagnostics aims to align clinical trials for its respiratory panel with the flu season, indicating an expectation of increased demand during these periods.

Co-Diagnostics, Inc. specializes in molecular diagnostics, developing and marketing diagnostic tests for infectious diseases, genetic disorders, and other health conditions. Its flagship product line includes the patented CoPrimer™ Technology, which enhances the accuracy and reliability of PCR testing. The company also offers Logix Smart™ Test Kits for detecting various infectious diseases and provides software solutions like CoDx™ Software for designing and optimizing PCR assays. The company is currently pivoting its focus to its proprietary Co-Dx PCR platform for point-of-care and at-home testing, which includes a pipeline of multiplex tests for Flu A, Flu B, COVID-19, and RSV.

Co-Diagnostics, Inc. operates in both domestic (United States) and international markets, with a strategic focus on addressing the needs of underserved regions. The company is actively expanding its global presence through strategic partnerships and joint ventures, including CoSara Diagnostics in India and CoMira Diagnostics in the Middle East and North Africa (MENA) region. Co-Diagnostics also participates in international trade fairs to showcase its technologies and engage with global audiences.

Co-Diagnostics, Inc. has been recognized for its innovation, including an award at the Utah Business 2025 Innovation Awards Summit for its Co-Dx PCR platform. The company's mission is to democratize molecular diagnostics by providing affordable, accurate, and accessible diagnostic solutions globally. Co-Diagnostics gained recognition for its role in the global response to the COVID-19 pandemic and its focus on affordability and accessibility, particularly in emerging markets, contributes positively to its brand image.

Co-Diagnostics, Inc.'s ownership structure is a mix of institutional, retail, and individual investors. Approximately 7.82% of the company's stock is owned by institutional investors, 4.48% by insiders, and 87.70% by public companies and individual investors. Major institutional shareholders include Vanguard Group Inc, Private Advisory Group LLC, Renaissance Technologies Llc, and BlackRock, Inc. Brent Satterfield is noted as the largest individual shareholder.